We’d love to hear your feedback on this activity. It helps us to continually improve our products.
At a glance: education, conference reports and articles
A-STAR is the The UK-Irish Atopic Eczema Systemic Therapy Register, an observational study investigating short and long-term safety and efficacy of systemic immuno-modulators for people with atopic dermatitis. The register also assesses the ‘real life’ cost of eczema treatments, comparing therapeutic costs with efficacy. touchDERMATOLOGY caught up with Prof. Carsten Flohr (Guy’s & St Thomas’ […]
BE HEARD I and II, were phase 3 clinical trials that investigated the efficacy and safety of bimekizumab for the treatment of hidradenitis suppurativa (HS). In this interview, we were delighted to speak with Prof. Christos C. Zouboulis (Brandenburg Medical School Theodor Fontane, Neuruppin, Germany) to discuss the rationale for investigating bimekizumab in HS, the […]
There are a number of cutaneous manifestations associated with lupus erythematosus, pushing forward for innovative approaches and emerging investigational therapeutics in clinical trials. touchDERMATOLOGY were delighted to speak with Dr. Victoria P. Werth (University Perelman School of Medicine, Philadelphia, PA, USA) to discuss the key developments, novel insights and future directions in the field of […]
OLYMPIA 2 (NCT04501679) was a phase 3, multicentre, double-blind study that investigated the IL-31 inhibitor nemolizumab for the treatment of prurigo nodularis in adults. touchDERMATOLOGY were delighted to speak with Prof. Adam Reich (University of Medicine, Wroclaw, Poland) around his analysis of OLYMPIA 2, looking at improvements in pain and patient reported outcomes. The abstract […]
Introduction: Janus kinase inhibitors (JAKis) have transformed the landscape of dermatological therapy over the last 2 years, with six United States Food and Drug Administration approvals and further clinical trials in progress.1 JAKis have proven highly efficacious in dermatological diseases, by blocking the JAK-signal transducer and activator of transcription (STAT) signalling pathway involved in numerous […]
The pathogenesis of cutaneous granulomatous disorders is incompletely understood and many unmet needs remain in the treatment paradigm.1 These disorders can be categorized into two main groups: those caused by infections and those associated with inflammatory skin conditions, among the most prevalent inflammatory disorders are granuloma annulare (GA) and cutaneous sarcoidosis (CS).1 The presentation of […]
Chronic spontaneous urticaria (CSU), a common and distressing skin condition driven by mast cells, is typically managed with a stepwise approach using second-generation H1-antihistamines, omalizumab and cyclosporine, as recommended by international guidelines. However, many patients with CSU do not respond optimally to this standardized treatment, likely due to the diverse underlying mechanisms involved. As a […]
We are delighted to welcome leading experts in the field of dermatology to our expert faculty. Click here to learn more.
Click here to view more medical education and communication. This content is sponsored by the pharmaceutical industry and developed by TMC.
View highlights and coverage from leading international Dermatology congresses
Read the latest articles from our peer reviewed Dermatology journals published by touchDERMATOLOGY
Get the latest clinical insights from touchDERMATOLOGY